We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PCB:NASDAQPCB Bancorp Analysis

Data as of 2026-06-04 - not real-time

$24.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

PCB Bancorp trades around $24, sitting just above its 20‑day SMA (≈24.29) which remains above the 50‑day (23.91) and 200‑day (22.38) averages, signaling a bullish alignment despite a bearish MACD histogram and a neutral RSI near 46. The stock is hovering near its technical support at 23.26 with resistance at 25.15, while volume has been on a decreasing trend, suggesting a cautious market participation. Its beta of 0.52 points to low market‑price sensitivity, though 30‑day volatility of roughly 22.7% indicates moderate price swings.
Fundamentally, PCB appears deeply undervalued: a trailing P/E of 8.6 versus an industry average of 16.4, price‑to‑book near parity at 1.04, and a dividend yield of 3.5% with a modest payout ratio under 30%. Strong profitability metrics—operating margin above 50% and ROE around 10.5%—combined with a solid cash position (~$267 M) against relatively low debt (~$68 M) underpin the valuation case. The DCF‑derived fair value of roughly $74 suggests significant upside, while analyst targets sit near $26, and the market sentiment index reflects “Extreme Greed,” hinting at bullish investor appetite.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support with bullish SMA hierarchy
  • Neutral momentum (RSI ~46) and bearish MACD histogram
  • Attractive dividend yield of 3.5% with low payout

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Undervaluation relative to peers (P/E 8.6 vs industry 16.4)
  • Strong profitability and low leverage
  • Potential price appreciation toward resistance and analyst target around $26

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF fair value indicating substantial upside
  • Sustainable dividend and solid balance sheet
  • Low beta and consistent earnings growth supporting long‑term stability

Key Metrics & Analysis

Financial Health

Revenue Growth17.60%
Profit Margin34.76%
P/E Ratio8.6
ROE10.52%
ROA1.23%
P/B Ratio1.0
Op. Cash Flow$44.9M
Industry P/E16.4

Technical Analysis

TrendBullish
RSI46.9
Support$23.26
Resistance$25.15
MA 20$24.29
MA 50$23.91
MA 200$22.38
MACDBearish
VolumeDecreasing
Fear & Greed Index91.73

Valuation

Fair Value$74.32
Target Price$26.00
Upside/Downside8.33%
GradeUndervalued
TypeValue
Dividend Yield3.50%

Risk Assessment

Beta0.81
Volatility22.69%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.